Carregant...
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
Idiopathic pulmonary fibrosis is a rare, progressive and fatal lung disease which affects approximately 5 million persons worldwide. Although pirfenidone and/or nintedanib treatment improves patients’ wellbeing, the prognosis of IPF remains poor with 5-year mortality rates still ranging from 70 to 8...
Guardat en:
| Publicat a: | J Clin Med |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6833050/ https://ncbi.nlm.nih.gov/pubmed/31561518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8101547 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|